National Health Partners, Inc. (NHPR)
Health has the most important value in our life, it is like a gift to livings which has no price and can’t be replaced. But unfortunately there are many reasons due to which medical care and health insurance gone very much expensive. The number of uninsured Americans continues to grow. There are serious health and financial consequences associated with being uninsured. Moreover, research shows that leaving a large share of the population without health insurance affects not only those who are uninsured, but also the health and economic wellbeing of the nation. Although the national debate over ensuring health coverage for more Americans periodically gains momentum, it then stalls-perhaps in part because not enough is known about both the benefits and the costs of expanding coverage to more, if not all, of the uninsured.

The access to affordable healthcare in the United States has become a luxury for some, although still subject to a seemingly arbitrary matrix of things. Government insurance products are available for the elderly, the permanently disabled, children from low-incomes, and those with failing kidneys. But how poor do you have to be to be eligible actually varies from state to state and also from year to year.

National Health Partners, Inc. recently announced the launch of a new network marketing program by one of its strategic partners, Xpress Healthcare, LLC. Xpress Healthcare has teamed up with CARExpress in an effort to revolutionize the discount healthcare industry while at the same time bringing financial freedom to families across the nation.

Xpress Healthcare has developed a first-class business platform that would enable brokers to develop their own business while generating strong monthly cash flows. By the end of the second quarter of 2011, Xpress Healthcare anticipates adding over 100 new brokers both participating in and promoting the CARExpress program and should enroll over 2,500 new members; the company also expects its growth to accelerate in the 3rd quarter as it anticipates recruiting an additional 200 new brokers which should generate over 10,000 new CARExpress sales.

According to the National Health Partners, Strong Sales are projected for 2nd Quarter From this New Strategic Partnership.

For more information about National Health Partners, Inc. visit its website at www.nationalhealthpartners.com

*********************************************************************************

American Video Teleconferencing Corp. (AVOT)
Rare earth elements or rare earth metals are a collection of seventeen chemical elements namely scandium, yttrium, and the fifteen lanthanides. The use of rare earth elements in modern technology has increased dramatically over the past years. For example, dysprosium has gained significant importance for its use in the construction of hybrid car motors. Unfortunately, this new demand has strained supply, and there is growing concern that the world may soon face a shortage of the materials. This is where the investment opportunity unfolds.

The unique properties (catalytic, chemical, electrical, metallurgical, magnetic and optical) of the Rare earth elements, and, in particular, both their specificity and versatility, have led to their being used for a wide variety of purposes. From relative obscurity, they are now important economically, environmentally and technologically.

American Video Teleconferencing Corp. believes the rare earths industry is where it wants to maintain a very strong focus and is looking to expand its holdings. AVOT is normally known for its business and efforts of exploration in Rare Earth Elements. According to the Company, it aggressively continues to search world-wide for opportunities in Precious, Base and Rare Earths metal projects in its future strategies.

**********************************************

Celsion Corp. (Nasdaq:CLSN) announced financial results for the year ended December 31, 2010 and addressed the progress of its clinical trials of ThermoDox®, Celsion’s proprietary heat-activated liposomal encapsulation of doxorubicin for the treatment of hepatocellular carcinoma (HCC), commonly referred to as primary liver cancer. ThermoDox® is currently being evaluated under a Special Protocol Assessment with the U.S. Food and Drug Administration (FDA) in a 600 patient pivotal Phase III trial (the HEAT study) in patients with non-resectable primary liver cancer and in a Phase I/II trial for patients with recurrent chest wall breast cancer. The HEAT study has been designated as a Priority Trial for liver cancer by the National Institutes of Health, has received Fast Track Designation from the FDA and has received Orphan Drug Designation in both the U.S. and Europe.

Celsion Corporation, an oncology drug development company, develops and commercializes targeted chemotherapeutic oncology drugs based on its proprietary heat-activated liposomal technology.

**********************************************

China Information Technology, Inc. (Nasdaq:CNIT) announced contract wins worth US$3.3 million to provide its core DPST and GIS solutions. The contracts secured include agreements to: supply Police-use GIS and PDA equipment for the Shenzhen City Traffic Police Mobile Law-enforcement System. The Company’s technology will enable highly efficient allocation and management of traffic police resources, while the PDA handsets held by police officers on the ground will enhance faster processing of traffic concerns. The System is a main component of the city’s intelligent traffic solution and a critical tool in relieving Shenzhen’s challenging traffic problems; install Police-use GIS platform in Jiaozuo and Hebi City of Henan Province under China’s National PGIS Standardization Project; and build a First Responder Coordination System for Anxi City of Fujian Province. The System will facilitate centralized reporting, command and execution capabilities, and will integrate fire, traffic and general police response systems into one consolidated platform, enabling rapid response to emergencies.

China Information Technology, Inc. specializes in Geographic Information System (GIS), digital public security, and hospital information systems in China.

**********************************************

Zalicus Inc. (Nasdaq:ZLCS) announced that it has been granted a composition-of-matter patent by the U.S. Patent and Trademark office covering its product candidate Synavive™. United States patent number 7,915,265 entitled “Combinations for the Treatment of Immunoinflammatory Disorders” provides broad coverage for Synavive™ through August 2025. This key patent, along with the existing issued method-of-use patent (US patent 7,253,155), fortifies the Synavive patent estate, which includes several patents and patent applications, granted and pending worldwide which collectively provide coverage of Synavive™ through at least 2028.

Zalicus Inc., a biopharmaceutical company, engages in the development of drug candidates focusing on the treatment of pain and inflammation.

Sign up for free stock alerts at http://www.pennygovernance.com/signup

***************************************

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. PennyGovernance.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold PennyGovernance.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur.(read more @ http://pennygovernance.com/disclaimer) Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (CRWE.OB) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period. Crown Equity Holdings Inc. (CRWE.OB) has received 3,000,000 shares of (144) restricted common stock from the company and 3,000,000 shares of free trading shares from a third party (PIERRE BESUCHET) for six months of advertisement services for National Health Partners Inc. (NHPR.OB).
Crown Equity Holdings Inc. (CRWE.OB) has received from the company 2,000,000 shares of (144) restricted common stock of American Video Teleconferencing Corp. (AVOT.PK) for 12 months IR Services and 1,000,000 shares of (144) restricted common stock for its IT services.